J&J, Elan close deal on Alzheimer's program
(Reuters) - Johnson & Johnson (JNJ.N) and Elan Corp Plc (ELN.N) said they have closed the deal under which J&J's newly formed unit Janssen Alzheimer Immunotherapy acquired all the assets and rights related to Elan's Alzheimer's Immunotherapy Program (AIP).
The unit will take over Elan's interest in a research partnership the Irish drugmaker had with Wyeth Pharmaceuticals, under the AIP, and continue to develop an Alzheimer's drug called bapineuzumab, it said.
The companies also closed the equity investment deal, under which J&J, through its affiliate Janssen Pharmaceutical, invested $885 million for an 18.4 percent stake in Elan, Johnson & Johnson said in a statement.
On September 14, J&J cut the amount it will pay for its 18.4 percent stake in Elan by $115 million to $885 million.
Shares of Johnson & Johnson were flat at $60.38 Thursday morning on the New York Stock Exchange, while those of Elan were up 1 percent at $7.64.
(Reporting by Shailesh Kuber in Bangalore; Editing by Unnikrishnan Nair)
- A top Federal Reserve official who is sometimes seen as a bellwether for U.S. monetary policy on Monday offered his voice to a growing contingent at the central bank that has argued for reducing the Fed's bond buying at a meeting next week.
SAN FRANCISCO - At Pinterest, the four-year-old online bulletin board service that is valued near $3.8 billion, some 70 percent of the users are female. But the company's board of directors is 100 percent male. | Video
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.